Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Basal Cell Carcinoma (BCC): early-phase trial registry

1 of 2 indexed Basal Cell Carcinoma (BCC) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Basal Cell Carcinoma (BCC): 2 US clinical trials tracked, 1 recruiting.

Basal Cell Carcinoma (BCC) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Nathalie Zeitouni, running 1 of these trials.

Enrollment posture brief

Registry condition basal-cell-carcinoma-bcc

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Basal Cell Carcinoma (this)50%
Open-enrollment share among volume-matched conditions near Basal Cell Carcinoma (BCC)

Basal Cell Carcinoma (BCC) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Basal Cell Carcinoma (BCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Basal Cell Carcinoma (BCC) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Named interventions

Most-linked intervention names on Basal Cell Carcinoma (BCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BMS-833923 (XL139) Drug
1 trials
BLU-U device model 4170E Device
1 trials
aminolevulinic acid HCL (ALA) Drug
1 trials

US sites by state

Facility locations filed on Basal Cell Carcinoma (BCC) trials. A trial with sites in several states counts in each.

Texas 1 trials
Minnesota 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Basal Cell Carcinoma (BCC) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Basal Cell Carcinoma (BCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Nathalie Zeitouni sponsors the most Basal Cell Carcinoma (BCC) trials on record, review their full trial history before evaluating a specific study. See Nathalie Zeitouni's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Basal Cell Carcinoma (BCC) condition card totals 2 registered trials; most-linked intervention BMS-833923 (XL139); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.